Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 8 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Introduction | 10 | 1 |
| Global Markets Direct Report Coverage | 10 | 1 |
| Osteosarcoma Overview | 11 | 1 |
| Therapeutics Development | 12 | 2 |
| Pipeline Products for Osteosarcoma Overview | 12 | 1 |
| Pipeline Products for Osteosarcoma Comparative Analysis | 13 | 1 |
| Osteosarcoma Therapeutics under Development by Companies | 14 | 2 |
| Osteosarcoma Therapeutics under Investigation by Universities/Institutes | 16 | 1 |
| Osteosarcoma Pipeline Products Glance | 17 | 2 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| Osteosarcoma Products under Development by Companies | 19 | 1 |
| Osteosarcoma Products under Investigation by Universities/Institutes | 20 | 1 |
| Osteosarcoma Companies Involved in Therapeutics Development | 21 | 20 |
| Advaxis, Inc. | 21 | 1 |
| Amgen Inc. | 22 | 1 |
| AVEO Pharmaceuticals, Inc. | 23 | 1 |
| Bayer AG | 24 | 1 |
| Bellicum Pharmaceuticals, Inc. | 25 | 1 |
| Celldex Therapeutics, Inc. | 26 | 1 |
| CytRx Corporation | 27 | 1 |
| Eleison Pharmaceuticals LLC | 28 | 1 |
| Exelixis, Inc. | 29 | 1 |
| Isofol Medical AB | 30 | 1 |
| MediaPharma s.r.l. | 31 | 1 |
| Merck &Co., Inc. | 32 | 1 |
| Merrimack Pharmaceuticals, Inc. | 33 | 1 |
| Netris Pharma S.A.S. | 34 | 1 |
| Novartis AG | 35 | 1 |
| Oncolys BioPharma Inc | 36 | 1 |
| Pfizer Inc. | 37 | 1 |
| Shionogi &Co., Ltd. | 38 | 1 |
| Teijin Pharma Limited | 39 | 1 |
| United Therapeutics Corporation | 40 | 1 |
| Osteosarcoma Therapeutics Assessment | 41 | 11 |
| Assessment by Monotherapy Products | 41 | 1 |
| Assessment by Target | 42 | 3 |
| Assessment by Mechanism of Action | 45 | 3 |
| Assessment by Route of Administration | 48 | 2 |
| Assessment by Molecule Type | 50 | 2 |
| Drug Profiles | 52 | 158 |
| 3D-QM Drug Profile | 52 | 1 |
| 3D-QMS Drug Profile | 53 | 1 |
| ADXS-HER2 Drug Profile | 54 | 4 |
| aldoxorubicin hydrochloride Drug Profile | 58 | 15 |
| AM-7209 Drug Profile | 73 | 1 |
| AU-101 Drug Profile | 74 | 1 |
| AV-203 Drug Profile | 75 | 3 |
| axitinib Drug Profile | 78 | 6 |
| cabozantinib s-malate Drug Profile | 84 | 18 |
| Cellular Immunotherapy for GD2 Expressing Solid Tumors Drug Profile | 102 | 2 |
| Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma Drug Profile | 104 | 1 |
| Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology Drug Profile | 105 | 1 |
| celyvir Drug Profile | 106 | 1 |
| CGS-200 Drug Profile | 107 | 1 |
| cisplatin SR Drug Profile | 108 | 2 |
| dihydroartemisinin Drug Profile | 110 | 1 |
| dinutuximab Drug Profile | 111 | 2 |
| everolimus Drug Profile | 113 | 12 |
| glembatumumab vedotin Drug Profile | 125 | 5 |
| irinotecan hydrochloride Drug Profile | 130 | 11 |
| ligerin Drug Profile | 141 | 1 |
| LLL-12 Drug Profile | 142 | 1 |
| Modufolin Drug Profile | 143 | 2 |
| Monoclonal Antibody for Osteosarcoma Drug Profile | 145 | 1 |
| Monoclonal Antibody to Inhibit GD2 for Oncology Drug Profile | 146 | 1 |
| Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma Drug Profile | 147 | 2 |
| MPE-8.3 Drug Profile | 149 | 1 |
| NP-137 Drug Profile | 150 | 1 |
| OBP-702 Drug Profile | 151 | 1 |
| Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer Drug Profile | 152 | 1 |
| pazopanib hydrochloride Drug Profile | 153 | 7 |
| pembrolizumab Drug Profile | 160 | 31 |
| Peptide to Target COX-2 and MAS-GPCR for Oncology Drug Profile | 191 | 2 |
| radium Ra 223 dichloride Drug Profile | 193 | 9 |
| RSF-101 Drug Profile | 202 | 1 |
| S-588410 Drug Profile | 203 | 2 |
| SEN-461 Drug Profile | 205 | 1 |
| Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma Drug Profile | 206 | 1 |
| Small Molecules to Inhibit CaMKII for Osteosarcoma Drug Profile | 207 | 1 |
| T-2GES Drug Profile | 208 | 1 |
| Vaccine for Osteosarcoma Drug Profile | 209 | 1 |
| Osteosarcoma Dormant Projects | 210 | 2 |
| Osteosarcoma Discontinued Products | 212 | 1 |
| Osteosarcoma Product Development Milestones | 213 | 9 |
| Featured News &Press Releases | 213 | 1 |
| Apr 28, 2016: FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma | 213 | 1 |
| Apr 20, 2016: Celldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin at the AACR Annual Meeting 2016 | 213 | 1 |
| Apr 13, 2016: Sarcoma Foundation of America Honors Advaxis for Advancements in Immunotherapy Platform | 214 | 1 |
| Mar 23, 2016: Advaxis Hosts Research Reception to Review Late-Breaking ADXS-HER2 at AACR Abstract | 215 | 1 |
| Mar 21, 2016: Survival Results with Advaxis HER2 Targeted Immunotherapy in Canine Osteosarcoma Published in Clinical Cancer Research | 215 | 1 |
| Mar 16, 2016: Merrimack to Present on ONIVYDE (irinotecan liposome injection) at the 2016 American Association for Cancer Research Annual Meeting | 216 | 1 |
| Jan 19, 2016: Advaxis Expands Intellectual Property for Lm Technology Platform | 216 | 1 |
| Dec 01, 2015: Advaxis Receives Orphan Drug Designation in the European Union for ADXS-HER2 for the Treatment of Osteosarcoma | 217 | 1 |
| Nov 30, 2015: CapGenesis Files Five Orphan Drug Designation Requests with the FDA and EMA for CGS-200 as a Topical Analgesic | 217 | 1 |
| Jul 21, 2015: Advaxis Expands Intellectual Property for Lm Technology Platform in HER2 | 218 | 1 |
| May 04, 2015: CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers | 219 | 1 |
| May 01, 2015: Eleison Announces Successful Completion of Stage 1 of its Phase II Trial of ILC (Inhaled Lipid-complexed Cisplatin) for Pediatric Bone Cancer | 220 | 1 |
| Apr 28, 2015: Advaxis Enhances Lm-LLO Cancer Immunotherapy Intellectual Property With USPTO Patent Addressing ADXS-HER2 | 220 | 1 |
| Nov 04, 2014: Advaxis to Present Data of ADXS-cHER2 at the Society for Immunotherapy of Cancer 29th Annual Meeting | 221 | 1 |
| Appendix | 222 | 2 |
| Methodology | 222 | 1 |
| Coverage | 222 | 1 |
| Secondary Research | 222 | 1 |
| Primary Research | 222 | 1 |
| Expert Panel Validation | 222 | 1 |
| Contact Us | 222 | 1 |
| Disclaimer | 223 | 1 |